Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 86 | SFEBES2022 | Next issue

Society for Endocrinology BES 2022

Harrogate, United Kingdom
14 Nov 2022 - 16 Nov 2022

Card image cap
SfE BES is returning to Harrogate in 2022. Join with endocrine specialists from across the UK and beyond for the Society for Endocrinology's flagship meeting.

Poster Presentations

Endocrine Cancer and Late Effects

ea0086p42 | Endocrine Cancer and Late Effects | SFEBES2022

Hydroxymethylation is dysregulated in pancreatic neuroendocrine tumours and associated with aberrant DNA methylation

English Katherine A , Selberherr Andreas , Shariq Omair A , O'Neill Eric , Lines Kate W , Thakker Rajesh V

Pancreatic neuroendocrine tumours (PNETs) have a lower mutational burden than other tumours, indicating that other mechanisms contribute to tumourigenesis. One such reported mechanism is DNA methylome dysregulation, however, inconsistencies have been observed between gene methylation and protein expression, potentially stemming from the use of standard methylation assessment methods which do not distinguish methylation (5Â’methylcytosine (5Â’mC), repressive mark) from ...

ea0086p43 | Endocrine Cancer and Late Effects | SFEBES2022

Gene-specific application of computational prediction tools aids the classification of rare missense variants in the diagnosis of hereditary endocrine tumour syndromes

Trip Ilse , McClean Joanne , Goudie David , Newey Paul

Introduction: The successful implementation of clinical genetic testing relies on accurate variant interpretation, as misclassification can result in significant harm to the patient and wider family. Missense single nucleotide variants (SNVs) pose a particular challenge, with current interpretation methods often unable to differentiate pathogenic variants from rare neutral variants, resulting in high numbers of variants of uncertain significance (VUS), and diagnostic uncertain...

ea0086p45 | Endocrine Cancer and Late Effects | SFEBES2022

Emergency Ambulatory Outpatient Management of Immune Checkpoint Inhibitor-mediated Hypocortisolaeamia

Ganawa Shawg , Muhammad Haris , Knight Tom , Dhage Shaishav , Hoong Ho Jan , Gupta Avinash , Lorigan Paul , Higham Claire , Cooksley Tim , Adam Safwaan

Background: Immunotherapy mediated adrenocorticotrpic hormone (ACTH) deficiency is an important toxicity related to immune-checkpoint inhibitors (ICPi) potentially resulting in significant morbidity. Early diagnosis and optimal management are essential and frequently necessitate inpatient hospital treatment. We have previously reported an ambulatory management pathway for ICPi-induced ACTH deficiency in 4 patients. We sought to report the outcomes of this pathway in a larger c...

ea0086p46 | Endocrine Cancer and Late Effects | SFEBES2022

Neuroendocrine Tumour (NET) patient satisfaction in the COVID-19 recovery period: A patient survey from a European Neuroendocrine Tumour Centre of Excellence

Dabke Tanvi , Finnen John , Austin Helen , Munir Alia

Introduction: The COVID-19 pandemic has affected patient care and experience. We assessed the evolution of NET patient perceptions during and peri-pandemic via a bespoke patient satisfaction survey.Methods: In February 2022, questionnaires with a pre-paid return envelope were posted out to 87 randomly selected NET patients, treated between January and December 2021. This consisted of 29 questions covering: initial contact, physician care and support, ill...

ea0086p47 | Endocrine Cancer and Late Effects | SFEBES2022

A Rare Occurrence of Phaeochromocytoma in an Adult with Previously Diagnosed Wilms Tumour - Case Report

Al Jumaah Ali , Gohil Shailesh , Levy Miles J , Reddy Narendra L , Bhake Ragini

Introduction: Phaeochromocytoma affects <1:100000 people per year. Wilms tumour (WT) affects almost 1:10000 children each year. Both tumours are associated with somatic genetic alterations: Phaeochromocytoma (RET, VHL, NF1, SDHA, SDHAF2, SDHB, SDHC, SDCD, TMEM127 and MAX); WT (WT1, 11p13, 11p15, tp53, NSD1, KDM3B, BRCA2). Both tumours affecting the same person have only been reported twice in the literature.Case Report: We report a lady who, at the a...

ea0086p193 | Endocrine Cancer and Late Effects | SFEBES2022

Clomiphene Citrate induced changes in the Estrogen and Estrogen receptors in the ovary of female Sprague-Dawley rats

Samson Aina Olawale , Iranloye Bolanle , Ckukwuduben Evangelshane , Rotimi Adebayo

Endocrine therapy in hormone sensitive cancers is on the increase and substances that reduce estrogen level and upregulate estrogen receptor can reduce activities of ovarian cancer. Clomiphene citrate (CC) is a selective estrogen receptor modulator. This study is aimed at investigating how different doses of CC affect estrogen level and level of alpha and beta estrogen receptors in the ovary of adult female rats. Fifty female Sprague-Dawley (SD) rats were divided into 5 groups...

ea0086p194 | Endocrine Cancer and Late Effects | SFEBES2022

The incidence and clinical significance of metabolically active brown adipose tissue in patients with pheochromocytomas and paragangliomas: A retrospective cohort study, systematic review and meta-analysis

Onyema Michael , Ostarijas Eduard , Minhas Raisa , Roy Aparajita , Kearney Jessica , Omran Asma , Zair Zoulikha , Reynolds Saira , Mulholland Nicola , Corcoran Benjamin , Halim Mohammad , Aylwin Simon , Dimitriadis Georgios K

There is limited research into the impact of active brown adipose tissue (aBAT) in patients with phaeochromocytomas and paragangliomas (PPGLs). A small body of evidence has shown that patients with PPGL patients can exhibit a high prevalence for aBAT recognized as ranging between 8 - 28% without specific correlation to germline mutations. Furthermore, it has been suggested that aBAT may be linked to increased mortality. Systematic searches of the Medical Literature Analysis an...

ea0086p195 | Endocrine Cancer and Late Effects | SFEBES2022

Repurposing Nandrolone, an Anabolic Steroid drug for Cancer Therapeutics: An In silico approach

Soremekun Oladimeji

Finding novel drugs and repurposing existing ones have gained increasing attention in addressing various setbacks faced by researchers in cancer research and treatment owing to the increased cancer rate, low efficacy, availability, and affordability of cancer drugs. Thus, the goal of this research is to repurpose nandrolone (ND), an inexpensive and widely available anabolic steroid, to a potential anticancer therapeutic candidate. A computer-aided drug design approach (CADD) i...

ea0086p196 | Endocrine Cancer and Late Effects | SFEBES2022

Prevalence of vitamin B12 deficiency in neuroendocrine tumour-Single Centre Experience

Tun Yee LaiLai , Myint Han Myint , Kapur Gaurav , Swe Myint Khin

Background: Neuroendocrine tumours (NET) are heterogenous group of tumours commonly arising from Gastro-pancreatic (GI) and pulmonary origins. Combination of bowel resection, disease related diarrhoea and somatostatin analogue therapy (SSA) can contribute to vitamin B12 deficiency (B12D). International guidelines do not suggest routine screening. Total serum cobalamin (B12) level can be falsely normal in patients with B12D. Cells take up B12 in the form of Holotranscobalamin (...

ea0086p197 | Endocrine Cancer and Late Effects | SFEBES2022

Immunotherapy and its impact on the endocrine system: Guidelines a need of the hour

Kirty Kaushiki , Mada Shrikanth , Pervez Muhammad

Introduction: Endocrine dysfunctions are a well known side effect of Immunotherapy with check point inhibitors. Endocrine dysfunction can begin as early as 6 days post initiation of therapy. There is a growing consensus that prompt recognition and early management of these endocrinopathies is essential; however there is a lack of specific guidelines regarding the monitoring of endocrine function. We present a case report of an asymptomatic patient known to have renal cell canc...

ea0086p198 | Endocrine Cancer and Late Effects | SFEBES2022

Acute life-threatening hyponatremia post first chemotherapy cycle with epirubicin and cyclophosphamide: Need for changing protocols?

Sharma Bhavna , Qureshi Asjid , Garg Ranjna , Rahman Mushtaqur

64 years old lady with history of breast cancer (post lumpectomy followed by radical mastectomy) received chemotherapy with Epirvlacin 140 mg and cyclophosphamide 600 mg 1 day prior. Past medical history included hypertension on ramipril and type 2 diabetes on diet control. Bloods on day of chemotherapy normal particularly sodium 135 mmols/l. Presented in 18 hours after 20 seconds tonic clonic seizure noted by family followed by abnormal flexion. Presented with GCS 7 which the...

ea0086p322 | Endocrine Cancer and Late Effects | SFEBES2022

Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer

Bruce Isla , Pang Lisa , Poole Amy , Fraser Jennifer

Neuroendocrine castrate resistant prostate cancer (NE-CRPC) is a lethal CRPC subtype that arises as prostate cancer cells transdifferentiate to neuroendocrine cells, evading the potent selective pressure of androgen deprivation therapies (ADT). Currently, clinicians lack biomarkers to detect NE-CRPC evolution and specific therapies to target it. With ~50% of prostate cancer (PC) patients receiving ADT and NE-CRPC accounting for ~25% of CRPC deaths, CRPC and NE-CRPC are a signi...

ea0086p323 | Endocrine Cancer and Late Effects | SFEBES2022

Managing PPGL surveillance in the COVID-19 recovery period: experience of a newly-established Endocrine Genetics MDT

Hunter Louise , Gibson Christine , Komlosy Nicci , Bastin Ambily , Balmuri Laxmi , Hanley Neil , Jennings Rachel , Woodward Emma , Lewis Alex

Background: Lifelong surveillance should be offered to people with hereditary phaeochromocytoma and paraganglioma (PPGL), including asymptomatic carriers of pathogenic gene variants. Regular biochemical and radiological surveillance aims to improve disease detection and prognosis. During the COVID-19 pandemic, outpatient appointments were cancelled or postponed. Departments continue to face large backlogs of work. Clinicians in the USA reported 15% PPGL patients missing at lea...